Hansa Biopharma ((SE:HNSA)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hansa Biopharma is conducting a clinical study titled ‘A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment’. The study aims to assess the efficacy and safety of imlifidase in enabling kidney transplantation in highly sensitized pediatric patients with end-stage renal disease. Key questions include whether imlifidase treatment can convert crossmatch results to negative and how well the transplanted kidney functions.
The intervention being tested is imlifidase, an IgG-degrading enzyme administered intravenously to neutralize IgG activities, facilitating kidney transplantation.
This interventional study is designed as an open-label, non-randomized trial with a single-group assignment. The primary purpose is treatment, with no masking involved, as there are no suitable control treatments available for comparison.
The study began on February 23, 2023, with the last update submitted on February 4, 2025. These dates are crucial as they indicate the study’s progression and the latest information available.
The update from this study could influence Hansa Biopharma’s stock performance positively, as successful results may enhance investor confidence and market position. The lack of effective alternatives in this niche market could further strengthen Hansa’s competitive edge.
The study is ongoing, with further details available on the ClinicalTrials portal.